Jw Pharmac Asset Resilience Ratio
Jw Pharmac asset resilience ratio. Jw Pharmac (001060) has an Asset Resilience Ratio of 7.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 001060 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jw Pharmac (2000–2025)
Asset resilience ratio of Jw Pharmac from 2000 to 2025. This chart shows how Jw Pharmac's Asset Resilience Ratio has changed over time. Read debt load of Jw Pharmac for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jw Pharmac's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Jw Pharmac's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩45.77 Billion | 7.36% |
| Total Liquid Assets | ₩45.77 Billion | 7.36% |
Asset Resilience Insights
- Limited Liquidity: Jw Pharmac maintains only 7.36% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jw Pharmac Industry Peers by Asset Resilience Ratio
Compare Jw Pharmac's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Jw Pharmac Asset Resilience Ratio by Year (2000–2025)
Jw Pharmac asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Jw Pharmac.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.65% | ₩22.11 Billion ≈ $14.98 Million |
₩605.27 Billion ≈ $410.18 Million |
-0.01pp |
| 2024-12-31 | 3.66% | ₩22.12 Billion ≈ $14.99 Million |
₩604.60 Billion ≈ $409.73 Million |
-8.48pp |
| 2023-12-31 | 12.14% | ₩78.29 Billion ≈ $53.05 Million |
₩645.04 Billion ≈ $437.13 Million |
-6.30pp |
| 2022-12-31 | 18.44% | ₩115.78 Billion ≈ $78.46 Million |
₩627.97 Billion ≈ $425.57 Million |
+13.34pp |
| 2021-12-31 | 5.10% | ₩32.30 Billion ≈ $21.89 Million |
₩633.05 Billion ≈ $429.01 Million |
-3.06pp |
| 2020-12-31 | 8.17% | ₩44.84 Billion ≈ $30.39 Million |
₩549.09 Billion ≈ $372.11 Million |
+8.16pp |
| 2016-12-31 | 0.00% | ₩20.00 Million ≈ $13.55K |
₩651.08 Billion ≈ $441.23 Million |
0.00pp |
| 2015-12-31 | 0.00% | ₩30.00 Million ≈ $20.33K |
₩613.48 Billion ≈ $415.75 Million |
-0.12pp |
| 2014-12-31 | 0.12% | ₩730.73 Million ≈ $495.20K |
₩594.12 Billion ≈ $402.63 Million |
-0.19pp |
| 2013-12-31 | 0.31% | ₩1.83 Billion ≈ $1.24 Million |
₩589.37 Billion ≈ $399.41 Million |
+0.05pp |
| 2012-12-31 | 0.26% | ₩1.58 Billion ≈ $1.07 Million |
₩603.15 Billion ≈ $408.74 Million |
+0.07pp |
| 2011-12-31 | 0.20% | ₩1.31 Billion ≈ $889.81K |
₩667.09 Billion ≈ $452.08 Million |
-3.66pp |
| 2006-12-31 | 3.86% | ₩19.89 Billion ≈ $13.48 Million |
₩515.85 Billion ≈ $349.58 Million |
-1.49pp |
| 2005-12-31 | 5.35% | ₩25.57 Billion ≈ $17.33 Million |
₩477.97 Billion ≈ $323.91 Million |
-0.45pp |
| 2004-12-31 | 5.80% | ₩26.55 Billion ≈ $17.99 Million |
₩457.56 Billion ≈ $310.08 Million |
-6.04pp |
| 2003-12-31 | 11.84% | ₩48.78 Billion ≈ $33.06 Million |
₩412.00 Billion ≈ $279.21 Million |
+5.83pp |
| 2002-12-31 | 6.02% | ₩23.19 Billion ≈ $15.72 Million |
₩385.60 Billion ≈ $261.32 Million |
-0.66pp |
| 2001-12-31 | 6.68% | ₩25.73 Billion ≈ $17.43 Million |
₩385.28 Billion ≈ $261.10 Million |
-2.16pp |
| 2000-12-31 | 8.84% | ₩35.14 Billion ≈ $23.81 Million |
₩397.46 Billion ≈ $269.35 Million |
-- |
About Jw Pharmac
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more